Safety and Efficacy of Oncoxin Plus Surafineb in Hepatocellular Carcinoma

Clinical Research Organization, Dhaka, Bangladesh60 enrolled

Overview

Oncoxin in combination with Surafenib is safe and results in improved survival in patients with hepatocellular carcinoma (HCC)

To assess therapeutic efficacy and safety of Oncoxin plus Surafenib in hepatocellular carcinoma To see if there is reduction in serum alpha fetoprotein level in hepatocellular carcinoma patients after administration of Oncoxin plus Surafenib To see if there is reduction tumor size and or number in hepatocellular carcinoma patients after administration of Oncoxin plus Surafenib To see if there is improvement of quality of life in hepatocellular carcinoma patients after administration of Oncoxin plus Surafenib To see if there is improved survival in hepatocellular carcinoma patients after administration of Oncoxin plus Surafenib

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Quality of Life

Interventions

OncoxinDIETARY_SUPPLEMENT

Syp Oncoxin 25 ml bd and Cap. Oncoxin bd for 180 days

SuranixDRUG

Tab Suranix 200 mg 2 tab bd and Syp Oncoxin 25 ml bd and Cap. Oncoxin bd for 180 days

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with HCC irrespective of etiology, age, gender and status of underlying liver disease. * Patients with HCC who are not suitable candidates for established modalities of treatment i.e. surgery and/or chemotherapy. * Patients with HCC who have evidence of tumor metastasis * Patients with HCC who are voluntarily unwilling to take established modalities of treatment i.e. surgery and/or chemotherapy. * Patients with HCC in whom all possible treatment options have been exhausted. Exclusion Criteria: * Patients with HCC who are suitable candidates for established modalities of treatment i.e. surgery and/or chemotherapy. * Patients with HCC who have no evidence of tumor metastasis * Patients with HCC who are willing to take established modalities of treatment i.e. surgery and/or chemotherapy. * Patients with HCC who are voluntarily unwilling to be included in the trial

Locations (1)

Farabi General Hospital

Dhaka, Bangladesh

RECRUITING

Outcomes

Primary Outcomes

Number of patients who have prolonged survival

To study the number of participants who have prolonged survival in months after receiving Oncoxin plus Surafenib for 24 weeks

Time frame: 24 weeks

Secondary Outcomes

Reduction in serum alpha-fetoprotein level and decrease in tumor size

To see whether Oncoxin plus Surafenib results in reduction in serum alpha-fetoprotein level in ng/ml and decrease in tumor size in mm in hepatocellular carcinoma patients off treatment for 24 weeks, after receiving Oncoxin plus Surafenib for 24 weeks.

Time frame: 24 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.